All Stories

  1. Population Pharmacokinetic Analysis and Simulation of Alternative Dosing Regimens for Biosimilars to Adalimumab and Etanercept in Patients with Rheumatoid Arthritis

    Article • Pharmaceutics, May 2024, MDPI AG

    James Bluett

  2. Towards Personalized Medicine in Rheumatoid Arthritis

    Article • Open Access Rheumatology Research and Reviews, May 2024, Taylor & Francis

    James Bluett

  3. The use of serum methotrexate level as an assessment of biochemical drug adherence in psoriasis

    Article • British Journal of Dermatology, March 2024, Oxford University Press (OUP)

    James Bluett

  4. The influence of deprivation in the outcomes of psoriatic arthritis within the UK—utilizing Outcomes of Treatment in Psoriatic Arthritis Study Syndicate (OUTPASS) data

    Article • Rheumatology Advances in Practice, January 2024, Oxford University Press (OUP)

    James Bluett

  5. Non-trough serum drug levels of adalimumab and etanercept are associated with response in patients with psoriatic arthritis

    Article • Rheumatology, December 2023, Oxford University Press (OUP)

    James Bluett

  6. Psoriatic arthritis: the role of self-reported non-adherence, non-trough drug levels, immunogenicity and conventional synthetic DMARD co-therapy in adalimumab and etanercept response

    Article • Rheumatology Advances in Practice, December 2023, Oxford University Press (OUP)

    James Bluett

  7. A proteomics study of rheumatoid arthritis patients on etanercept identifies putative biomarkers associated with clinical outcome measures

    Article • Rheumatology, June 2023, Oxford University Press (OUP)

    James Bluett

  8. Development of a sensitive biochemical assay for the detection of tofacitinib adherence

    Article • Analytical Methods, January 2023, Royal Society of Chemistry

    James Bluett

  9. Do genetics contribute to TNF inhibitor response prediction in Psoriatic Arthritis?

    Article • The Pharmacogenomics Journal, October 2022, Springer Science + Business Media

    James Bluett

  10. Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial

    Article • The Lancet Respiratory Medicine, September 2022, Elsevier

    James Bluett

  11. Comparative Genetic Analysis of Psoriatic Arthritis and Psoriasis for the Discovery of Genetic Risk Factors and Risk Prediction Modeling

    Article • Arthritis & Rheumatology, August 2022, Wiley

    James Bluett

  12. Effects of temporarily suspending low-dose methotrexate treatment for 2 weeks after SARS-CoV-2 vaccine booster on vaccine response in immunosuppressed adults with inflammatory conditions: protocol for a multicentre randomised controlled trial and neste...

    Article • BMJ Open, May 2022, BMJ

    James Bluett

  13. Pharmacogenetics of TNF inhibitor response in rheumatoid arthritis utilizing the two-component disease activity score

    Article • Pharmacogenomics, November 2020, Future Medicine

    James Bluett

  14. Translating research into clinical practice: quality improvement to halve non-adherence to methotrexate

    Article • Rheumatology, June 2020, Oxford University Press (OUP)

    James Bluett

  15. Therapeutic monitoring of TNF inhibitors for rheumatoid arthritis: evidence required following NICE’s recommendations

    Article • Rheumatology Advances in Practice, January 2020, Oxford University Press (OUP)

    James Bluett

  16. Pharmacogenetics of methotrexate response in rheumatoid arthritis: an update

    Article • Pharmacogenomics, January 2020, Future Medicine

    James Bluett

  17. Development and validation of a methotrexate adherence assay

    Article • Annals of the Rheumatic Diseases, June 2019, BMJ

    James Bluett

  18. Prediction of response to methotrexate in rheumatoid arthritis

    Article • Expert Review of Clinical Immunology, April 2018, Taylor & Francis

    James Bluett

  19. Precision Medicine in Rheumatoid Arthritis

    Article • Rheumatic Disease Clinics of North America, August 2017, Elsevier

    James Bluett

  20. Quantitative Online Liquid Chromatography–Surface-Enhanced Raman Scattering (LC-SERS) of Methotrexate and its Major Metabolites

    Article • Analytical Chemistry, May 2017, American Chemical Society (ACS)

    James Bluett, Drupad Trivedi

  21. HLA-A 31:01 is not associated with the development of methotrexate pneumonitis in the UK population: results from a genome-wide association study

    Article • Annals of the Rheumatic Diseases, May 2017, BMJ

    James Bluett

  22. Psychological factors predict adherence to methotrexate in rheumatoid arthritis; findings from a systematic review of rates, predictors and associations with patient-reported and clinical outcomes

    Article • RMD Open, January 2016, BMJ

    James Bluett

  23. Erratum: Corrigendum: Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis

    Article • Nature Communications, July 2015, Springer Science + Business Media

    James Bluett

  24. Epidemiology and Genetics

    Article • June 2015, Oxford University Press (OUP)

    James Bluett

  25. Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis

    Article • Nature Communications, February 2015, Springer Science + Business Media

    James Bluett

  26. A HPLC-SRM-MS based method for the detection and quantification of methotrexate in urine at doses used in clinical practice for patients with rheumatological disease: a potential measure of adherence

    Article • The Analyst, January 2015, Royal Society of Chemistry

    James Bluett

  27. Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort

    Article • Rheumatology, September 2014, Oxford University Press (OUP)

    James Bluett

  28. 143. North West Regional Audit: Management of Polymyalgia Rheumatica

    Article • Rheumatology, April 2014, Oxford University Press (OUP)

    James Bluett

  29. Cervical Spine Calcinosis in Systemic Sclerosis

    Article • The Journal of Rheumatology, September 2013, The Journal of Rheumatology

    James Bluett

  30. Association of a complement receptor 1 gene variant with baseline erythrocyte sedimentation rate levels in patients starting anti-TNF therapy in a UK rheumatoid arthritis cohort: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics ...

    Article • The Pharmacogenomics Journal, July 2013, Springer Science + Business Media

    James Bluett

  31. Use of ENCODE and eQTL data to identify potential functional genetic variants at the 5q31 psoriatic arthritis susceptibility locus

    Article • The Lancet, February 2013, Elsevier

    James Bluett

  32. What Have Genome-Wide Studies Told Us About Psoriatic Arthritis?

    Article • Current Rheumatology Reports, April 2012, Springer Science + Business Media

    James Bluett